NCT00626002

Open Label Continuation Study in Moderate to Severe Psoriasis

A Phase 3, Multi-center, Open-label Continuation Study in Moderate to Severe Plaque Psoriasis in Subjects Who Completed a Preceding Psoriasis Study With ABT-874

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 2,301 (actual)
• Sponsor: AbbVie (prior sponsor, Abbott) · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate long term safety, efficacy and tolerability of ABT-874 in adults with moderate to severe psoriasis.

Conditions

• Moderate to Severe Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	ABT-874	100mg ABT-874 administered SQ every 4 wks for approximately 204 weeks

Timeline

• Start date: 2008-02-01
• Primary completion: 2011-10-01
• Completion: 2011-10-01
• First posted: 2008-02-29
• Last updated: 2013-01-30

Locations

152 sites across 14 countries: United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Spain, Sweden, Switzerland, United Kingdom